Fiasp (insulin aspart injection) NDC 0169-3201

NDC codes

FDA NDC Directory

Product NDC (as listed)0169-3201Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00169-3201Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0169-3201-11	00169320111	1 VIAL, GLASS in 1 CARTON (0169-3201-11) / 10 mL in 1 VIAL, GLASSMarketed from Oct 20, 2017
0169-3201-90	00169320190	1 VIAL, GLASS in 1 CARTON (0169-3201-90) / 10 mL in 1 VIAL, GLASSMarketed from Oct 20, 2017 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fiasp
Generic name (nonproprietary): insulin aspart injection
Active ingredients: Insulin aspart — 100 [iU]/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Novo Nordisk
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 208751
Marketing start: Oct 20, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Insulin (Chemical structure)
Identifiers: Product ID 0169-3201_133d5f6e-b40f-47b6-ab47-10dc37114d79SPL ID 133d5f6e-b40f-47b6-ab47-10dc37114d79SPL set ID 834e7efc-393f-4c55-9125-628562a8a5cfRxCUI 1986354, 1986356, 2205454, 2642808, 2642809, 2730170, 2730172, 2730174UNII D933668QVX
Pharmacologic class: Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400169320111 followed by a unit qualifier and the quantity

Package 00169-3201-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 21, 2023.

Indications (excerpt from the label)

FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. • FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 208751

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 208751
Product	Strength	Form · route	Labeler	Product NDC
Fiaspinsulin aspart injection	Insulin aspart 100 [iU]/mL	Injection, SolutionSubcutaneous	Novo Nordisk	0169-3204
Fiaspinsulin aspart injection	Insulin aspart 100 [iU]/mL	Injection, SolutionSubcutaneous	Novo Nordisk	0169-3205
Fiaspinsulin aspart	Insulin aspart 100 [iU]/mL	Injection, SolutionSubcutaneous	Novo Nordisk	0169-3206